title: Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance.
abstract: The risk stratification and final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Our principal goals were to identify and validate targetable metabolic drivers relevant to pathogenesis of NPC using a published transcriptome. One prominently downregulated gene regulating amino acid metabolism was found to be argininosuccinate synthetase (ASS1). Attributable to epigenetic DNA methylation, ASS1 deficiency may link to the therapeutic sensitivity to the arginine-depriving agents and promote tumor aggressiveness through its newly identified tumor suppressor function. ASS1 immunohistochemistry was therefore examined in a well-defined cohort of 124 NPC biopsy specimens and in the neck lymph node metastases of another ten independent cases. For the latter, bisulphite pyrosequencing was performed to evaluate the extent of ASS1 gene methylation. ASS1 protein deficiency was identified in 64 of 124 cases (51.6%), significantly related to T3-T4 status (p = 0.006), and univariately associated with inferior local recurrence-free survival (p = 0.0427), distant metastasis-free survival (DMFS; p = 0.0036), and disease-specific survival (DSS; p = 0.0069). Together with advanced AJCC stages III-IV, ASS1 protein deficiency was also independently predictive of worse outcomes for the DFMS (p = 0.010, hazard ratio = 2.241) and DSS (p = 0.020, hazard ratio = 1.900). ASS1 promoter hypermethylation was detected in eight of ten neck nodal metastatic lesions by bisulphite pyrosequencing and associated with ASS1 protein deficiency (p < 0.001). In summary, ASS1 protein deficiency was seen in approximately a half of NPCs and associated with advanced T classification, DNA methylation, and clinical aggressiveness, consistent with its tumor suppressor role. This aberration may render pegylated arginine deiminase as a promising strategy for ASS1-deficient NPCs.
authors.affiliation: Departments of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors.forename: Jui
authors.initials: J
authors.lastname: Lan
authors.forename: Hui-Chun
authors.initials: HC
authors.lastname: Tai
authors.forename: Sung-Wei
authors.initials: SW
authors.lastname: Lee
authors.forename: Tzu-Ju
authors.initials: TJ
authors.lastname: Chen
authors.forename: Hsuan-Ying
authors.initials: HY
authors.lastname: Huang
authors.forename: Chien-Feng
authors.initials: CF
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000096:biosynthesis; D001124:Argininosuccinate Synthase / Q000235:genetics* / Q000378:metabolism; D053898:Biosynthetic Pathways; D002277:Carcinoma; D016000:Cluster Analysis; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000596:Amino Acids; D001124:Argininosuccinate Synthase
references.citation: Cancer. 2004 Feb 15;100(4):826-33
references.pmid: 14770441
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Br J Cancer. 2010 Sep 28;103(7):954-60
references.pmid: 20808309
references.citation: PLoS One. 2011 May 04;6(5):e19645
references.pmid: 21573193
references.citation: J Clin Pathol. 2012 Mar;65(3):248-53
references.pmid: 22081787
references.citation: Nat Genet. 2001 Nov;29(3):263-4
references.pmid: 11687795
references.citation: Oncogene. 2010 Jan 21;29(3):442-50
references.pmid: 19881551
references.citation: Expert Rev Anticancer Ther. 2010 Sep;10(9):1439-50
references.pmid: 20836679
references.citation: Mol Cancer Ther. 2010 Mar;9(3):535-44
references.pmid: 20159990
references.citation: Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):202-7
references.pmid: 18538504
references.citation: Cancer Res. 2005 Sep 15;65(18):8125-33
references.pmid: 16166286
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6730-8
references.pmid: 16170180
references.citation: Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):597-604
references.pmid: 21300475
references.citation: Int J Cancer. 2010 Jun 15;126(12):2762-72
references.pmid: 20104527
references.citation: Int J Cancer. 2009 Sep 15;125(6):1454-63
references.pmid: 19533750
references.citation: Semin Cancer Biol. 2002 Dec;12(6):451-62
references.pmid: 12450731
references.citation: Clin Cancer Res. 2013 Jun 1;19(11):2861-72
references.pmid: 23549872
references.citation: J Clin Oncol. 2003 Feb 15;21(4):631-7
references.pmid: 12586799
references.citation: Cancer. 2007 Jan 15;109(2):313-21
references.pmid: 17154159
references.citation: Cancer Cell. 2004 May;5(5):423-8
references.pmid: 15144950
references.citation: Curr Opin Oncol. 2008 May;20(3):264-9
references.pmid: 18391624
references.citation: Semin Cancer Biol. 2002 Dec;12(6):421-9
references.pmid: 12450728
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7126-31
references.pmid: 17145837
references.citation: Nat Rev Cancer. 2011 Feb;11(2):85-95
references.pmid: 21258394
references.citation: Cancer Res. 2006 Aug 15;66(16):7999-8006
references.pmid: 16912175
references.citation: Eur J Biochem. 2003 May;270(9):1887-99
references.pmid: 12709047
references.citation: Nat Rev Cancer. 2010 Apr;10(4):267-77
references.pmid: 20300106
references.citation: Mol Cancer Ther. 2009 Dec;8(12):3223-33
references.pmid: 19934275
references.citation: Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):356-64
references.pmid: 18355980
references.citation: Semin Cancer Biol. 2005 Aug;15(4):247-53
references.pmid: 15886013